Grant Writing
A proposal has to do three things at once. It has to convince reviewers that the problem matters, that the idea is worth funding, and that you and your team can actually do it. Every section of every application serves one of those three claims.
This page is about how those claims get made differently at the two agencies most infectious-disease researchers write for, the NIH and the NSF. The mechanisms and career stages sit in scientific pathways. The one page that carries the argument at NIH gets taken apart in the specific aims page. Here we hold the two agencies side by side, because the same idea has to be dressed differently for each.
What every proposal is arguing#
Reviewers read fast and read many. They are looking for reasons to say yes and, more often, reasons to say no. Three questions decide it.
- Does the problem matter? Not “is this interesting” but “does the field, or human health, or basic understanding move if this gets answered.”
- Is the idea worth funding? Is there a real gap, is the approach the right one to close it, and is there something here that is not just the next increment.
- Can you do it? Track record, preliminary data where expected, a plan that survives contact with reality, and a budget and timeline that fit the work.
A proposal that answers all three and still loses usually lost on the second. The problem was real and the team was strong, but the idea read as safe, or the gap was vague, or the approach had no contingency when the first experiment fails.
NIH: health and disease#
NIH exists to enhance health and reduce illness. Every proposal has to connect, eventually, to a disease or a health outcome, even the basic-science ones. The structure follows from that mission.
The narrative is two pieces. The one-page Specific Aims frames the problem, names the gap, states the central hypothesis, and lists two to four aims, each with a method and a measurable outcome. The Research Strategy then argues three things in order.
- Significance. Why the problem is an important barrier to progress in health, and what changes if you succeed.
- Innovation. What is genuinely new in the concept, the method, or the model, and why the current approaches fall short.
- Approach. The detailed plan for each aim, with preliminary data, expected outcomes, and, most tellingly, the pitfalls and alternative strategies you have already thought through.
Applications go to a study section, a panel of peer scientists, and are scored one through nine on Significance, Investigators, Innovation, Approach, and Environment. Rigor and reproducibility are now scored, not decorative. Say how the design controls bias, how the sample size is justified, and how you will handle relevant biological variables. Most funded grants were resubmissions. Treat the first summary statement as the opening of a conversation and answer every reviewer point in the revision.
NSF: fundamental advance and broader impacts#
NSF funds the progress of science itself, not health outcomes. For infectious disease this is the ecology and evolution of pathogens, the mathematics of transmission, the theory rather than the clinical payoff. If your pitch is “this will improve patient care,” it is an NIH pitch.
The narrative is the Project Description, usually fifteen pages, and it answers two merit-review criteria that carry equal weight.
- Intellectual Merit. The potential to advance knowledge. For a math-biology proposal this means new mathematics, or a nontrivial application of existing mathematics, that is necessary and not merely useful for the biological question.
- Broader Impacts. The benefit to society beyond the findings. Training of students, broadening who participates in science, open tools and data, public engagement. These have to be specific activities with a plan and a way to measure them, not a paragraph of good intentions bolted on at the end.
NSF review is a panel plus ad hoc reviewers, and there is no formal resubmission letter. You revise, you may draw a different panel, and program-officer feedback guides where to push.
The same idea, two proposals#
Take one project. You want to estimate how much transmission of a respiratory pathogen happens before symptoms appear.
For NIH, the argument runs through health. The gap is that symptom-based isolation policy rests on an unmeasured pre-symptomatic fraction, and getting it wrong costs cases and lives. Significance is the failure of a control strategy. Innovation is the censoring-aware method that recovers the fraction from imperfect contact-tracing data. The payoff is a defensible isolation policy for the next outbreak.
For NSF, the argument runs through understanding and generality. The gap is that the timing of infectiousness relative to symptoms is a basic feature of host-pathogen biology we cannot yet estimate cleanly across pathogens. Intellectual Merit is the new estimator and what it reveals about the evolution of transmission timing. Broader Impacts are the open software, the graduate training at the math-biology interface, and the reusable method other groups adopt.
Same data, same model, two different reasons to fund it. Read the solicitation before you decide which one you are writing, and for NIH, talk to a program officer first. Aligning to the mission is half the argument.
A note on SBIR and STTR#
SBIR and STTR are a separate track, run through both agencies, and the customer is different. These are small-business awards, and the point of Phase I is not discovery but de-risking a product enough to justify Phase II investment. Every aim needs a quantitative go/no-go threshold, not just an interesting result. The commercialization plan matters as much as the science, and the customer is usually a company or a government buyer, not a patient. STTR additionally requires a partnership between the small business and a research institution with documented work shares. If the goal is a commercial product, this is the track. If the goal is a paper or a policy, it is not.
A compact skeleton#
Specific Aims / Project Summary. One specific fact establishing importance, narrowing to a concrete gap, then the central hypothesis or objective.
Aim 1. A testable objective. Method: how. Outcome: the measurable result.
Aim 2. A second aim sharing the hypothesis but not depending on Aim 1’s success.
Significance / Intellectual Merit. Why the problem matters, in the currency the agency funds: health impact for NIH, fundamental advance for NSF.
Innovation. What is new and why current approaches are insufficient.
Approach. The plan per aim, with preliminary data, rigor and reproducibility, and named pitfalls with alternatives.
Broader Impacts (NSF) or health payoff (NIH). Training, dissemination, and societal benefit for NSF; the change to health or practice for NIH.
Budget and timeline. A realistic budget justified line by line, and a schedule that shows the aims fit the funded period.
Why it matters#
The idea is the smaller part of a funded grant. The larger part is knowing which agency’s mission your idea serves and building the argument in that agency’s terms. The same experiment is a health-impact story to one reviewer and a fundamental-advance story to another, and the writer’s job is to make the right story to the right panel, then back it with a plan they cannot find a reason to reject.